相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Hagop M. Kantarjian et al.
BLOOD (2012)
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
H. Jean Khoury et al.
BLOOD (2012)
Three decades of transplantation for chronic myeloid leukemia: what have we learned?
Jiri Pavlu et al.
BLOOD (2011)
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib
Amina Haouala et al.
BLOOD (2011)
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Simona Soverini et al.
BLOOD (2011)
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Jorge E. Cortes et al.
BLOOD (2011)
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
Amr R. Ibrahim et al.
BLOOD (2011)
Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
Wayne W. Chan et al.
CANCER CELL (2011)
The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile
Christopher A. Eide et al.
CANCER RESEARCH (2011)
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy
Benjamin Hanfstein et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
Simona Soverini et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Sensitive Detection of BCR-ABL1 Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent Therapy
Wendy T. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Hagop M. Kantarjian et al.
LANCET ONCOLOGY (2011)
Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed
Lina Eliasson et al.
LEUKEMIA RESEARCH (2011)
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib
Paul W. Manley et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib
Marius Dohse et al.
DRUG METABOLISM AND DISPOSITION (2010)
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
Elias Jabbour et al.
BLOOD (2009)
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Martin C. Mueller et al.
BLOOD (2009)
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
Elias Jabbour et al.
BLOOD (2009)
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
Simona Soverini et al.
BLOOD (2009)
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Gianantonio Rosti et al.
BLOOD (2009)
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
Lucien Noens et al.
BLOOD (2009)
Efficacy of Imatinib Dose Escalation in Patients With Chronic Myeloid Leukemia in Chronic Phase
Hagop M. Kantarjian et al.
CANCER (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?
Massimo Breccia et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib
Thomas Ernst et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
Jane F. Apperley et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Timothy Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Conformational disturbance in Abl kinase upon mutation and deregulation
Roxana E. Iacob et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia
Athina Giannoudis et al.
BLOOD (2008)
Molecular basis explanation for imatinib resistance of BCR-ABL due to T3151 and P-loop mutations from molecular dynamics simulations
Tai-Sung Lee et al.
CANCER (2008)
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: Therapeutic implications
Devendra K. Hiwase et al.
CLINICAL CANCER RESEARCH (2008)
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate
Michael Brave et al.
CLINICAL CANCER RESEARCH (2008)
Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib
Maitreyee Hazarika et al.
CLINICAL CANCER RESEARCH (2008)
Imatinib mesylate for the treatment of chronic myeloid leukemia
Simona Soverini et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Thomas Ernst et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib
Thomas Ernst et al.
HAEMATOLOGICA (2008)
Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib
Navratna Vajpai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase
Ji Wu et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
A. Hochhaus et al.
LEUKEMIA (2008)
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib
Jamshid S. Khorashad et al.
BLOOD (2008)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
Philipp le Coutre et al.
BLOOD (2008)
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
Deborah L. White et al.
BLOOD (2007)
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
Jorge Cortes et al.
BLOOD (2007)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M. Kantarjian et al.
BLOOD (2007)
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Jane F. Apperley
LANCET ONCOLOGY (2007)
Crystal structure of the T315I mutant of abl kinase
Tianjun Zhou et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2007)
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Neil P. Shah et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
Francois Guilhot et al.
BLOOD (2007)
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
Jorge Cortes et al.
BLOOD (2007)
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Andreas Hochhaus et al.
BLOOD (2007)
Patterns of somatic mutation in human cancer genomes
Christopher Greenman et al.
NATURE (2007)
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
Simona Soverini et al.
HAEMATOLOGICA (2007)
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
Alfonso Quintas-Cardama et al.
CANCER (2007)
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib
D. W. Sherbenou et al.
LEUKEMIA (2007)
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants
Brian J. Skaggs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia
Simona Soverini et al.
CLINICAL CANCER RESEARCH (2006)
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
Miriam Puttini et al.
CANCER RESEARCH (2006)
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib
Ian J. Griswold et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants
John S. Tokarski et al.
CANCER RESEARCH (2006)
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients:: a retrospective analysis from the French intergroup of CML (Fi(φ)-LMC GROUP)
F. E. Nicolini et al.
LEUKEMIA (2006)
The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib
C Miething et al.
LEUKEMIA (2006)
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib
JS Khorashad et al.
LEUKEMIA (2006)
BCR-ABL kinase domain mutations in chronic myeloid leukemia - Not quite enough to cause resistance to imatinib therapy?
T Lange et al.
CELL CYCLE (2005)
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia
S Kimura et al.
BLOOD (2005)
Selecting and deselecting imatinib-resistant clones:: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL
FXE Gruber et al.
LEUKEMIA (2005)
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients; correlation with clonal cytogenetic evolution but not response to therapy
SG Willis et al.
BLOOD (2005)
Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients
S Hayette et al.
LEUKEMIA RESEARCH (2005)
Drug resistance in cancer: Principles of emergence and prevention
NL Komarova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Double-gradient-denaturing-gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients
N Sorel et al.
CLINICAL CHEMISTRY (2005)
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia
S Soverini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center -: A 4.5-year follow-up
T Lahaye et al.
CANCER (2005)
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance
MR Burgess et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Clinical pharmacokinetics of imatinib
B Peng et al.
CLINICAL PHARMACOKINETICS (2005)
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2
Y Dai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Active transport of imatinib into and out of cells: implications for drug resistance
J Thomas et al.
BLOOD (2004)
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib
S Soverini et al.
CLINICAL CHEMISTRY (2004)
Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to imatinib
JAE Irving et al.
CLINICAL CHEMISTRY (2004)
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib
HK Al-Ali et al.
HEMATOLOGY JOURNAL (2004)
Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique (vol 82, pg 284, 2003)
KA Kreuzer et al.
ANNALS OF HEMATOLOGY (2003)
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
S Branford et al.
BLOOD (2003)
Several Bcr-Ab1 kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
AS Corbin et al.
BLOOD (2003)
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
FX Mahon et al.
BLOOD (2003)
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia
HM Kantarjian et al.
BLOOD (2003)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy
A Hochhaus et al.
LEUKEMIA (2002)
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
S Roumiantsev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to ST157, and they can pre-exist to the onset of treatment
C Roche-Lestienne et al.
BLOOD (2002)
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
S Branford et al.
BLOOD (2002)
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571:: a prospective study
N von Bubnoff et al.
LANCET (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)